Reportlinker Adds Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infectio...(li Methicillin resistant staphyloco...),Health

This report covers nosocomial infection diagnosis and therapeutics in a broad sense. It does not go into the detail of the dynamics of individual products in the marketplace. It discusses, however, the status of the field of nosocomial infection diagnostics and therapeutics, as a setting-specific field of application.

The Most Recent and Relevant Epidemiological Statistics on HAIs

There is no 'noscomial infection' market per se, it is reflected in sales and revenues of all infectious disease testing and therapeutics. Therefore Kalorama's market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products).

In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing needs.

Estimates of Market Impact

As mentioned above, the primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at t
'/>"/>